Regulatory Meetings. If requested by Vertex, CFFT will arrange for one or more representatives of CFFT to participate in meetings between representatives of Vertex and any of the FDA, the EMEA and Koseisho (MHW Japan), to the extent that Vertex reasonably believes that representatives from CFFT would further the regulatory approval process.
Appears in 4 contracts
Samples: Research, Development and Commecialization Agreement (Vertex Pharmaceuticals Inc / Ma), Development and Commecialization Agreement (Royalty Pharma PLC), Development and Commecialization Agreement (Royalty Pharma PLC)
Regulatory Meetings. If requested by Vertex, CFFT will arrange for one or more representatives of CFFT to participate in meetings between representatives of Vertex and any of the FDA, the EMEA and Koseisho (MHW Japan), to the extent that Vertex reasonably believes that representatives from CFFT would further the regulatory approval process. Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been separately filed with the Commission.
Appears in 2 contracts
Samples: Confidential Treatment Requested (Vertex Pharmaceuticals Inc / Ma), Confidential Treatment Requested (Vertex Pharmaceuticals Inc / Ma)
Regulatory Meetings. If requested by Vertex, CFFT will arrange for one or more representatives of CFFT to participate in meetings between representatives of Vertex and any of the FDA, the EMEA and Koseisho (MHW Japan), to the extent that Vertex reasonably believes that representatives from CFFT would further the regulatory approval process.. Confidential Treatment Requested by Royalty Pharma plc Pursuant to 17 C.F.R. Section 200.83
Appears in 1 contract
Samples: Research, Development and Commecialization Agreement (Royalty Pharma PLC)
